National Policy Resources—Local Advocacy Results

As cancer care professionals who experience the challenges of providing quality cancer care first-hand, IOS members are well positioned to educate decision-makers on how coverage and reimbursement issues affect community oncology. State and federal legislation can have a significant impact on the financial viability of local cancer programs, which is why it's so important that our members make their voices heard.

In an effort to provide resources needed to effectively advocate on the issues that are important to them, our redesigned advocacy webpage features activity from the Centers for Medicare & Medicaid Services (CMS), national healthcare coverage through the Association of Community Cancer Centers (ACCC), local news articles and webinars, and more.

We want to hear from you! If there is a specific piece of legislation you want to know more about, an important resource we're missing, or if you want to get more involved, please contact us!

State Advocacy

On July 1, 2021, the Indiana Department of Health, Indiana Board of Pharmacy, Indiana Department of Insurance, and the Indiana Family and Social Services Administration released its Specialty Drug Channel Management Report.

The report identifies the recent effects of white bagging in Indiana and why the practice of white bagging is a safety risk for patients. In addition to state and federal considerations, the report provides examples of patient experiences and outlines best practices for reimbursement and communications.

Stay tuned for more communications and advocacy opportunities from the Indiana Oncology Society as we work with these state organizations to ensure that we provide the best care for patients with cancer across the Hoosier state.


Federal Advocacy

IOS Joins 400+ Organizations in Support of MCED Legislation
May 5, 2022

The Indiana Oncology Society (IOS) joined more than 400 organization from all 50 states to urge Congress to pass the Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act (H.R.1946/S.1873) this year. This legislation would create a pathway for MCED tests to be covered by the Medicare program following approval by the Food and Drug Administration (FDA).

Read the Letter 



Advocacy In the News

New CMS Data Shows Increased Medicare Telemedine Utilization During COVID-19

On December 3, 2021, the Centers for Medicare and Medicaid Services (CMS) released a new data snapshot, featuring telemedicine utilization data that make the case for expanded and permanent telehealth coverage for Medicare beneficiaries.

These data are about people with Medicare who used telemedicine services between March 1, 2020, and February 8, 2021, and they come from Medicare Fee-for-Service data, Medicare Advantage encounter data, and Medicare enrollment information.

CMS states that the agency has seen large increases in telemedicine use during the defined time frame with variations across geographic and demographic groups. This increase is credited to the agency's expansion of telemedicine services during the COVID-19 public health emergency.

The snapshot shows that telemedicine utilization (e.g., telehealth, e-visits, and virtual check-ins) increased from 910,490 unique users pre-pandemic to 28,255,180 unique users during the pandemic. And the majority (53%) of the pandemic's telemedicine users were Medicare beneficiaries. To see a detailed breakdown of these data, read the full snapshot report.

For more information on Medicare's telemedicine expansions, visit its dedicated telehealth website.

Posted 12/9/2021

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us 

Oncology State Societies at ACCC: Snapshot from the 2022 ASCO Annual Meeting

In this clip, Stephanie Van Winkle, Executive Director of the Oncology State Societies at ACCC, gives an overview of the important work the Oncology State Societies does to empower its members around state and federal advocacy issues, and help them support cancer care delivery in their state. Join today